CUMBERLAND PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Mar 7, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 7, 2025

CPIX$5.37+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	2024	2023
Revenues:
Net product revenue	$36,537,704	$37,513,492
Other revenue	1,330,241	2,039,015
Net revenues	37,867,945	39,552,507
Costs and expenses:
Cost of products sold	6,585,972	6,066,611
Selling and marketing	17,023,023	18,451,765
Research and development	4,816,206	5,834,229
General and administrative	11,126,901	10,651,915
Amortization and impairment	4,748,252	8,102,648
Total costs and expenses	44,300,354	49,107,168
Operating loss	(6,432,409)	(9,554,661)
Interest income	334,444	286,854
Other income	—	2,828,871
Other income - settlement	—	475,000
Other income - gain on insurance proceeds	237,089	346,800
Interest expense	(605,508)	(667,861)
Loss before income taxes	(6,466,384)	(6,284,997)
Income tax benefit (expense)	22,669	(45,769)
Net loss	(6,443,715)	(6,330,766)
Net (income) loss at subsidiary attributable to noncontrolling interests	(36,055)	51,446
Net loss attributable to common shareholders	$(6,479,770)	$(6,279,320)
Loss per share attributable to common shareholders:
Basic	$(0.46)	$(0.44)
Diluted	$(0.46)	$(0.44)
Weighted-average common shares outstanding:
Basic	14,060,272	14,298,774
Diluted	14,060,272	14,298,774

See accompanying notes to consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.